26 February 2016 - Shield Therapeutics plc is pleased to announce that the European Commission has granted marketing authorisation across all member states for its wholly owned product, Feraccru, as a treatment for adults with iron deficiency anaemia (IDA) in patients with inflammatory bowel disease.

For more details, go to: http://www.shieldtherapeutics.com/2016/02/26/feraccru-receives-marketing-authorisation-in-europe/